Siirry sisältöön

Cover picture

Otsikko5.jpg

Time:
Friday, May 24, 2019 at 11:30

Venue: Mauno Conference Center, President's Auditorium, BioCity, Tykistökatu 6, Turku  map

Organiser: Turku Stem Cell Transplantation unit, Tyks, Turku University Hospital & University of Turku

Programme: See thepreliminary programme. The programme is still subject to some changes.

Keynote speaker:
Prof. Nicolaus Kröger, University Hospital Hamburg-Eppendorf, Germany

Guest speakers:
Prof. Robert Zeiser, University Medical Center Freiburg, Germany
Prof. Katharina Fleischhauer, University Hospital Essen, Germany
Prof. Johanna Ivaska, University of Turku, Centre for Biotechnology, Finland
MD, PhD. Mikko Keränen, Department of Hematology, Helsinki University Hospital

Registration: www.lyyti.fi/reg/TurkuSymposium_24052019

Registration deadline: by May 6th 2019.

Symposium dinner: The symposium dinner will be organized right after the scientific programme. More information coming soon!

5 hours theoretical training credits have been applied from University of Turku for the following specialities: clinical hematology, infectious diseases, internal medicine, clinical chemistry, pediatrics, oncology.

For enquiries related to the Turku Symposium, please contact coordinator Jaana Pakola, email firstname.lastname (at) tyks.fi.

Sponsors
Symposium includes an exhibition provided by our sponsoring companies. The exhibition will be situated in the assembly hall of Mauno conference center next to the auditorium where the scientific program will take place.
You will find our 2019 sponsors listed below during the spring.

"Dear Friends and Colleagues,

You are cordially invited to attend the XXI Turku Symposium on Stem Cell Transplantation which will be held in Turku, Finland, May 24, 2019.

We are honored to have outstanding speakers in the field of allogeneic hematopoietic stem cell transplantations. During the last decade, after several attempts, we have seen a successful approach of haploidentical transplants. T-cell replete haploidentical transplantation has been an important milestone, not only because offering an opportunity to get a suitable donor for the great majority of the patients, but also because of an plausible decrease of the risk of severe GVHD, which might also open new insights to the pathophysiology of GVHD. Furthermore, haploidentical transplant might also serve as a platform for immunological interventions to prevent post-transplant relapse. In addition to allogeneic transplants, interesting issues in both basic cancer biology, pathogenesis of acute GVHD, and clinical transplantation will be covered.

We are very pleased to welcome you in Turku."

SCT Director.jpg​Maija Itälä-Remes
Adjunct professor
Director of Stem Cell Transplantation unit
Turku University Hospital


 

Päivitetty: 15/02/2019 08:01
Luotu: 08/01/2019 11:07